TP-12 ; Thematic Poster ; The Effect of Fluticasone/Salmoterol Added to Tiotropium versus Tiotropium about Cough or Phlegm in the Patients with COPD: Post Hoc Analysis of the SUPER Study = TP-12 ; Thematic Poster ; The Effect of Fluticasone/Salmoterol Added to Tiotropium versus Tiotropium about Cough or Phlegm in the Patients with COPD: Post Hoc Analysis of the SUPER Study

다국어 초록 (Multilingual Abstract)

The patients with chronic obstructive pulmonary disease (COPD) show various symptoms. In addition to breathlessness, cough and phlegm are the major symptoms. Although many clinical trials revealed that breathlessness is improved by inhaled therapy in COPD patients, the effect of these inhalers on cough or phlegm was not evaluated.The SUPER study demonstrated the improvement in lung function of the fluticasone/salmeterol (FSC) added to tiotropium statistically superior to that of tiotropium alone. We performed a post hoc analysis of the SUPER study with particular focus on cough and phlegm.At baseline, 89 (tiotropium +FSC vs tiotropium 22% vs 21%) patients complained that they suffered cough in most days a week. 106 (27% vs. 25%) patients did in a few days a week. 151 (38% vs 36%) patients did in only with chest infection. 134 (tiotropium +FSC vs tiotropium 33% vs 32%) patients complained that they suffered phlegm in most days a week. 126 (31% vs 30%) patients did in a few days a week. 101 (25% vs 25%) patients did in only with chest infection. At the end of study, 148(40% vs 32%) patients showed the improvement on cough, 190(43.1% vs 49.0%) patients had no change, and 74 (17% vs 19%) patients aggravated the cough. 42 (38% vs 31%) patients showed the improvement on phlegm, 76 (15% vs 22%) patients had no change, and 194 (47% vs 48%) patients aggravated the phlegm. In the patients suffered cough in most days a week at the baseline, tiotropium+FSC group had significantly more improvement in cough than tiotropium alone (76% vs 55%, p=0.047). There was no effect of phlegm between groups. In COPD patients presenting with cough, tiotropium combined FSC treatment was more helpful than tiotropium alone. However the effect of triple inhaled treatment about phlegm in COPD patients were similar to tiotropium alone.The patients with chronic obstructive pulmonary disease (COPD) show various symptoms. In addition to breathlessness, cough and phlegm are the major symptoms. Although many clinical trials revealed that breathlessness is improved by inhaled therapy in COPD patients, the effect of these inhalers on cough or phlegm was not evaluated.The SUPER study demonstrated the improvement in lung function of the fluticasone/salmeterol (FSC) added to tiotropium statistically superior to that of tiotropium alone. We performed a post hoc analysis of the SUPER study with particular focus on cough and phlegm.At baseline, 89 (tiotropium +FSC vs tiotropium 22% vs 21%) patients complained that they suffered cough in most days a week. 106 (27% vs. 25%) patients did in a few days a week. 151 (38% vs 36%) patients did in only with chest infection. 134 (tiotropium +FSC vs tiotropium 33% vs 32%) patients complained that they suffered phlegm in most days a week. 126 (31% vs 30%) patients did in a few days a week. 101 (25% vs 25%) patients did in only with chest infection. At the end of study, 148(40% vs 32%) patients showed the improvement on cough, 190(43.1% vs 49.0%) patients had no change, and 74 (17% vs 19%) patients aggravated the cough. 42 (38% vs 31%) patients showed the improvement on phlegm, 76 (15% vs 22%) patients had no change, and 194 (47% vs 48%) patients aggravated the phlegm. In the patients suffered cough in most days a week at the baseline, tiotropium+FSC group had significantly more improvement in cough than tiotropium alone (76% vs 55%, p=0.047). There was no effect of phlegm between groups. In COPD patients presenting with cough, tiotropium combined FSC treatment was more helpful than tiotropium alone. However the effect of triple inhaled treatment about phlegm in COPD patients were similar to tiotropium alone.